• Revenue: $19.4 million for Q4 2024, an 11% increase from Q4 2023; $73.2 million for fiscal year 2024, a 12% increase from 2023.

• Gross Margin: 76.1% for Q4 2024, slightly down from 76.9% in Q4 2023; 76.9% for fiscal year 2024, up from 76.5% in 2023.

• Domestic Sales: Increased 21% to $16.5 million in Q4 2024.

• International Sales: Decreased 24% to $2.9 million in Q4 2024.

• Device Revenue: Increased 12% to $14.3 million in Q4 2024; 13% to $52 million for fiscal year 2024.

• Pump Revenue: Increased 34% in Q4 2024; 36% for fiscal year 2024.

• Operating Expenses: $9 million or 46% of revenue for Q4 2024; $34 million or 47% of revenue for fiscal year 2024.

• Operating Income: $5.8 million for Q4 2024; $22 million for fiscal year 2024.

• Net Income (GAAP): $0.40 per diluted share for Q4 2024; $1.50 per diluted share for fiscal year 2024.

• Net Income (Non-GAAP): $0.44 per diluted share for Q4 2024; $1.66 per diluted share for fiscal year 2024.

• Cash from Operations: $6 million for Q4 2024, up from $3.9 million in Q4 2023.

• Free Cash Flow: $2.9 million for Q4 2024, down from $3.3 million in Q4 2023.

• Warning! GuruFocus has detected 5 Warning Signs with IRMD.

Release Date: February 13, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• iRadimed Corp (NASDAQ:IRMD) reported a record quarter with revenue exceeding $19.4 million, marking the 14th consecutive record quarter.

• Gross profit was strong at 76.1%, with GAAP diluted earnings per share increasing by 11% from Q4 2023.

• Domestic sales increased by 21% to $16.5 million, accounting for 85% of total revenue for Q4 2024.

• The company has a strong backlog entering 2025, providing good visibility for the first half of the year.

• The new facility construction is progressing well, with completion expected by June, which will support future growth.

Negative Points

• International sales decreased by 24% to $2.9 million, indicating challenges in global markets.

• The gross margin for Q4 2024 was slightly below the previous year's quarter, at 76.1% compared to 76.9%.

• Operating expenses increased to $9 million, driven by higher sales and marketing expenses.

• Free cash flow decreased to $2.9 million from $3.3 million in the same period in 2023, due to ongoing capital expenditures.

• The company faces potential delays in FDA clearance for the new pump, which could impact revenue projections for 2025.

Q & A Highlights

Q: In terms of next year, should we assume that the sales force will focus more on the monitor business, and how do you see 2025 forming on the top line? A: Yes, we will be highlighting sales of the monitor in 2025, and we expect the monitor business to be significantly impacted. We have already seen strong bookings for the monitor in the fourth quarter, indicating more to come in 2025. - Roger Susi, CEO